Browse Studies — Arctuva

Phase 1

Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas

This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if a…

T-cell LymphomasNK-Cell LymphomasT-cell Prolymphocytic Leukemia+1 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05010005

Phase 1

Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study

Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pemb…

NK-Cell LymphomaNK-Cell LeukemiaPeripheral T Cell Lymphoma

Estimated

~$10 – $6,250

New York Medical CollegeNCT03719105

The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the infor…

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+28 more